PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The study is intended to investigate the safety of BYL719 and AUY922 in patients with
advanced gastric cancer, and to determine the MTD and/or RDE of both drugs in combination. In
addition, the preliminary efficacy of BYL719 in combination with AUY922, and the
pharmacokinetics of both drugs will be assessed. Patients will be eligible for this study, if
their tumors carry either a molecular alteration of PIK3CA, or an amplification of HER2.
The study includes a dose escalation part followed by a safety expansion phase.